Navigation Links
Renowned Hudson Valley ENT Sleep Specialist Selected to Participate in FDA Study of New Obstructive Sleep Apnea Treatment
Date:6/24/2013

Middletown, NY (PRWEB) June 24, 2013

Ofer Jacobowitz, M.D., PhD. FAASM, FAAOA, an Otolaryngologist and Sleep Medicine specialist, is one of only three doctors in the United States who have been selected by the sponsor to participate in the current FDA study for ImThera Medical’s aura6000tm, a neurostimulation device for treating Obstructive Sleep Apnea (OSA). Dr. Jacobowitz, a nationally and internationally recognized expert in sleep apnea, has implanted the device in five patients to date. The procedures were performed at Orange Regional Medical Center (ORMC) located in Middletown, NY, where Dr. Jacobowitz serves as Associate Medical Director of the ORMC Center for Sleep. Dr. Jacobowitz is the only physician conducting the study in New York State and the study is the only one taking place on the East Coast.

The aura6000 device delivers electrical pulses to generate targeted motions of the tongue in order to keep patients’ airways open during sleep. The device is implanted in a surgical procedure that averages approximately 60 minutes. The system uses ImThera Medical’s patented Targeted Hypoglossal Neurostimulation (THN™ Sleep Therapy) to focus neurostimulation on certain muscles of the tongue, and acts as a “pacemaker” preventing the tongue from blocking the airways during sleep, the primary cause of obstruction in a majority of sleep apnea patients. The aura6000 is one of the world’s smallest implantable rechargeable stimulators and does not require external sensors to function. Prior to sleep, patients simply turn it on with the push of a button on a remote controller.

ImThera Medical, Inc. announced European CE Mark (Conformité Européenne) approval of its aura6000 system in March 2012. The device is investigational in the US.

“I am extremely honored to have been selected to conduct the FDA trials,” said Dr. Jacobowitz. “Many sleep apnea patients will not wear cumbersome air pressure devices to get a good, healthy and safe night’s sleep and others will not even seek treatment for the same reason. New innovations offer hope to those patients for whom the appropriate treatment for their condition may seem as onerous as the condition itself. I look forward to the results from my patients and those of my esteemed colleagues.” In addition to Dr. Jacobowitz’s study in New York, additional study sites are in Chicago and Denver in the United States, and in Europe in Brussels and several cities in Germany.

Dr. Jacobowitz is a member of the sleep disorders and the medical drugs and devices committees at the American Academy of Otolaryngology/Head and Neck Surgery and is a founding member of the International Surgical Sleep Society. He serves on the clinical outcomes task force of the American Academy of Sleep Medicine and has served as Chair of the sleep-related breathing disorders section and all membership sections from 2012 to 2013. He is also an assistant Professor of Otorhinolaryngology Head and Neck Surgery at the Mount Sinai Hospital in NY, Columbia/New York Presbyterian Hospital in NY and a practicing partner at Hudson Valley ENT in Middletown, New York.

More than 800,000 patients in the U.S. are diagnosed with OSA annually. The industry estimates that as many as 38 million Americans may suffer from OSA and that approximately only 20 percent of the population is getting treatment today. Left untreated, OSA may lead to many serious consequences, including: hypertension, congestive heart failure, atrial fibrillation, stroke, type II diabetes, weight gain, depression and traffic accidents.

About ImThera Medical, Inc and THN Sleep Therapy
ImThera Medical has developed a novel neurostimulation system for the treatment of OSA. The aura6000 system delivers the THN Sleep Therapy via a multi-contact electrode array that can selectively stimulate different portions of the hypoglossal nerve to increase muscle tone in key tongue muscles during sleep, thereby opening the upper airway. In addition, the aura6000 neurostimulator cycles stimulation between several tongue muscles to prevent fatiguing any single muscle.

ImThera’s mission is to provide a safe and effective alternative for OSA patients who cannot comply with CPAP so that they can live longer and enjoy better lives, while substantially reducing health care costs related to the serious complications associated with untreated obstructive sleep apnea.

CAUTION: The aura6000 is an investigational device, limited by United States law to investigational use.

Read the full story at http://www.prweb.com/releases/2013/6/prweb10854380.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Renowned Rim Fitments Expert, SizeItUp Officially Declares The Launch of Database Integration for The 2012 Porsche 911 Coupe
2. Renowned Regulatory Representatives From Mainland China and Taiwan to Discuss Need for Collaboration at DIA Meeting
3. Renowned Rim Fitments Expert, SizeItUp Launches The Database Integrations for the 2012 Nissan GT-R
4. Renowned Sales Trainer, Frank Rumbauskas, to Lead Ellickson USA's Sales Training
5. Chopra Center Launches Online Workshop “Manifesting: Living the Life of Your Dreams” – Featuring World-Renowned Teacher and Best-Selling Author Dr. Jean Houston
6. Renowned Skin Specialists Facial Attraction Reveal Anti-Acne Treatment Campaign on Nova 100 Radio And Limited 46% Discount Offer
7. A Better Approach to Spinal Bone Spur Surgery Renowned Spine Surgeon Dr. Kaixuan Liu Explains Endoscopic Foraminotomy
8. Internationally Renowned Dermatologist Discusses Best Treatments for Rosacea
9. World Renowned Ayurvedic Physician, Dr. Akhilesh Sharma, to Offer in Bogotá Advanced Workshop on June 15th, 2013
10. June Healthcare Conference Dives into Expertise from Renowned National Healthcare Leaders
11. Renowned Digestive Health Expert, Brenda Watson, is Back on Public Television in June with Her Breakthrough Health Show on #1 Killer of Americans
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... ... December 07, 2016 , ... ... financial consultation services to residents in the Sacramento/Folsom region, is initiating a charity ... facility. , The Another Choice Another Chance treatment center in Sacramento works to ...
(Date:12/7/2016)... ... December 07, 2016 , ... A. Kevin Spann Insurance, ... families throughout the Five Boroughs, is launching a charity drive to raise funds that ... the traditions and spirit of marines and Navy FMF Corpsmen. Working closely with the ...
(Date:12/7/2016)... ... December 07, 2016 , ... Facial plastic surgeon, Dr. John D. Rachel ... a portion of proceeds to two local organizations: North Chicago Animal Control and Friends ... is a team of authorized and trained volunteers who support rescued animals held ...
(Date:12/7/2016)... ... December 07, 2016 , ... The medical profession is well aware that heart ... major study analyzing heart attacks among 138,602 people recorded a 35% higher number of ... would all agree of course–no time of year is a good time for a ...
(Date:12/7/2016)... Norwalk, CT (PRWEB) , ... December 07, 2016 ... ... the Integrated Infertility and Wellness (IFW) Program at Reproductive Medicine Associates of Connecticut ... which now has a team of three acupuncturists to help patients realize their ...
Breaking Medicine News(10 mins):
(Date:12/7/2016)... 7, 2016  Ionis Pharmaceuticals, Inc. (NASDAQ: IONS ), ... a company overview at the BMO Capital Markets Prescriptions for Success ... NY . A live webcast of the presentation ... Ionis website.  The replay will be available within 48 hours and ... ...
(Date:12/7/2016)... (NYSE: LCI ) today announced that the company will ... Conference on December 14, 2016 at 9:20 a.m. (ET) at the ... In addition, the company will host one-on-one meetings with ... Boston Healthcare Conference taking place on December 13, 2016 at the ... , , ...
(Date:12/6/2016)... -- Alopexx Oncology, LLC announced data from a Phase I ... composed of interleukin-2 and a CD20-targeting monoclonal antibody. The ... as Rituxan and maintains the activities of both the ... tumor targeting, engagement of the immune system, and induction ... study (abstract #95954) were presented at the 58 th ...
Breaking Medicine Technology: